Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10%
Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year
treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin